vs
MIMEDX GROUP, INC.（MDXG）与Rocket Lab Corp（RKLB）财务数据对比。点击上方公司名可切换其他公司
Rocket Lab Corp的季度营收约是MIMEDX GROUP, INC.的1.5倍（$179.7M vs $118.1M），MIMEDX GROUP, INC.净利率更高（12.9% vs -29.5%，领先42.3%），Rocket Lab Corp同比增速更快（35.7% vs 27.1%），过去两年Rocket Lab Corp的营收复合增速更高（39.2% vs 18.1%）
MiMedx是一家总部位于美国佐治亚州玛丽埃塔的生物医疗企业，成立于2008年。该企业以胎盘、羊膜囊、脐带等分娩组织为原料，开发可用于植皮手术的医用真皮产品，在生物再生医疗领域开展业务。
Rocket Lab是公开上市的航空航天制造商及发射服务提供商，旗下Electron轨道火箭主打小型卫星发射，截至2026年1月已成功完成超75次任务，是全球现役发射次数最多的小型运载火箭。公司还开发了Electron的亚轨道改型HASTE用作高超音速技术测试平台，下一代可复用中型运载火箭Neutron目前也在研发中。
MDXG vs RKLB — 直观对比
营收规模更大
RKLB
是对方的1.5倍
$118.1M
营收增速更快
RKLB
高出8.6%
27.1%
净利率更高
MDXG
高出42.3%
-29.5%
两年增速更快
RKLB
近两年复合增速
18.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $118.1M | $179.7M |
| 净利润 | $15.2M | $-52.9M |
| 毛利率 | 83.9% | 38.0% |
| 营业利润率 | 17.8% | -28.4% |
| 净利率 | 12.9% | -29.5% |
| 营收同比 | 27.1% | 35.7% |
| 净利润同比 | 104.2% | -1.1% |
| 每股收益（稀释后） | $0.10 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MDXGRKLB
| Q4 25 | $118.1M | $179.7M | ||
| Q3 25 | $113.7M | $155.1M | ||
| Q2 25 | $98.6M | $144.5M | ||
| Q1 25 | $88.2M | $122.6M | ||
| Q4 24 | $92.9M | $132.4M | ||
| Q3 24 | $84.1M | $104.8M | ||
| Q2 24 | $87.2M | $106.3M | ||
| Q1 24 | $84.7M | $92.8M |
净利润MDXGRKLB
| Q4 25 | $15.2M | $-52.9M | ||
| Q3 25 | $16.7M | $-18.3M | ||
| Q2 25 | $9.6M | $-66.4M | ||
| Q1 25 | $7.0M | $-60.6M | ||
| Q4 24 | $7.4M | $-52.3M | ||
| Q3 24 | $8.1M | $-51.9M | ||
| Q2 24 | $17.6M | $-41.6M | ||
| Q1 24 | $9.3M | $-44.3M |
毛利率MDXGRKLB
| Q4 25 | 83.9% | 38.0% | ||
| Q3 25 | 83.5% | 37.0% | ||
| Q2 25 | 81.1% | 32.1% | ||
| Q1 25 | 81.2% | 28.8% | ||
| Q4 24 | 81.8% | 27.8% | ||
| Q3 24 | 81.8% | 26.7% | ||
| Q2 24 | 83.0% | 25.6% | ||
| Q1 24 | 84.7% | 26.1% |
营业利润率MDXGRKLB
| Q4 25 | 17.8% | -28.4% | ||
| Q3 25 | 19.5% | -38.0% | ||
| Q2 25 | 12.5% | -41.3% | ||
| Q1 25 | 9.4% | -48.3% | ||
| Q4 24 | 11.9% | -38.9% | ||
| Q3 24 | 13.3% | -49.5% | ||
| Q2 24 | 26.9% | -40.7% | ||
| Q1 24 | 15.6% | -46.4% |
净利率MDXGRKLB
| Q4 25 | 12.9% | -29.5% | ||
| Q3 25 | 14.7% | -11.8% | ||
| Q2 25 | 9.8% | -46.0% | ||
| Q1 25 | 8.0% | -49.5% | ||
| Q4 24 | 8.0% | -39.5% | ||
| Q3 24 | 9.6% | -49.6% | ||
| Q2 24 | 20.2% | -39.2% | ||
| Q1 24 | 10.9% | -47.7% |
每股收益（稀释后）MDXGRKLB
| Q4 25 | $0.10 | $-0.09 | ||
| Q3 25 | $0.11 | $-0.03 | ||
| Q2 25 | $0.06 | $-0.13 | ||
| Q1 25 | $0.05 | $-0.12 | ||
| Q4 24 | $0.05 | $-0.11 | ||
| Q3 24 | $0.05 | $-0.10 | ||
| Q2 24 | $0.12 | $-0.08 | ||
| Q1 24 | $0.06 | $-0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $166.1M | $1.0B |
| 总债务越低越好 | $18.0M | $152.4M |
| 股东权益账面价值 | $256.5M | $1.7B |
| 总资产 | $342.7M | $2.3B |
| 负债/权益比越低杠杆越低 | 0.07× | 0.09× |
8季度趋势，按日历期对齐
现金及短期投资MDXGRKLB
| Q4 25 | $166.1M | $1.0B | ||
| Q3 25 | $142.1M | $976.7M | ||
| Q2 25 | $118.9M | $688.1M | ||
| Q1 25 | $106.4M | $428.4M | ||
| Q4 24 | $104.4M | $419.0M | ||
| Q3 24 | $88.8M | $442.4M | ||
| Q2 24 | $69.0M | $496.8M | ||
| Q1 24 | $48.5M | $492.5M |
总债务MDXGRKLB
| Q4 25 | $18.0M | $152.4M | ||
| Q3 25 | — | $347.0M | ||
| Q2 25 | — | $346.5M | ||
| Q1 25 | — | $345.9M | ||
| Q4 24 | $19.0M | $345.4M | ||
| Q3 24 | — | $61.2M | ||
| Q2 24 | — | $64.2M | ||
| Q1 24 | — | $66.8M |
股东权益MDXGRKLB
| Q4 25 | $256.5M | $1.7B | ||
| Q3 25 | $238.9M | $1.3B | ||
| Q2 25 | $216.6M | $688.5M | ||
| Q1 25 | $202.8M | $431.3M | ||
| Q4 24 | $193.1M | $382.5M | ||
| Q3 24 | $181.0M | $419.8M | ||
| Q2 24 | $168.0M | $455.2M | ||
| Q1 24 | $155.7M | $478.9M |
总资产MDXGRKLB
| Q4 25 | $342.7M | $2.3B | ||
| Q3 25 | $319.0M | $2.2B | ||
| Q2 25 | $291.1M | $1.6B | ||
| Q1 25 | $270.4M | $1.3B | ||
| Q4 24 | $263.9M | $1.2B | ||
| Q3 24 | $243.9M | $1.2B | ||
| Q2 24 | $230.2M | $1.2B | ||
| Q1 24 | $221.7M | $1.2B |
负债/权益比MDXGRKLB
| Q4 25 | 0.07× | 0.09× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 0.50× | ||
| Q1 25 | — | 0.80× | ||
| Q4 24 | 0.10× | 0.90× | ||
| Q3 24 | — | 0.15× | ||
| Q2 24 | — | 0.14× | ||
| Q1 24 | — | 0.14× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $25.0M | $-64.5M |
| 自由现金流经营现金流 - 资本支出 | — | $-114.2M |
| 自由现金流率自由现金流/营收 | — | -63.6% |
| 资本支出强度资本支出/营收 | — | 27.6% |
| 现金转化率经营现金流/净利润 | 1.64× | — |
| 过去12个月自由现金流最近4个季度 | — | $-321.8M |
8季度趋势，按日历期对齐
经营现金流MDXGRKLB
| Q4 25 | $25.0M | $-64.5M | ||
| Q3 25 | $29.3M | $-23.5M | ||
| Q2 25 | $14.4M | $-23.2M | ||
| Q1 25 | $5.3M | $-54.2M | ||
| Q4 24 | $18.8M | $-2.4M | ||
| Q3 24 | $19.6M | $-30.9M | ||
| Q2 24 | $21.8M | $-13.0M | ||
| Q1 24 | $6.0M | $-2.6M |
自由现金流MDXGRKLB
| Q4 25 | — | $-114.2M | ||
| Q3 25 | — | $-69.4M | ||
| Q2 25 | — | $-55.3M | ||
| Q1 25 | — | $-82.9M | ||
| Q4 24 | — | $-23.9M | ||
| Q3 24 | — | $-41.9M | ||
| Q2 24 | — | $-28.3M | ||
| Q1 24 | — | $-21.8M |
自由现金流率MDXGRKLB
| Q4 25 | — | -63.6% | ||
| Q3 25 | — | -44.8% | ||
| Q2 25 | — | -38.3% | ||
| Q1 25 | — | -67.6% | ||
| Q4 24 | — | -18.1% | ||
| Q3 24 | — | -40.0% | ||
| Q2 24 | — | -26.7% | ||
| Q1 24 | — | -23.5% |
资本支出强度MDXGRKLB
| Q4 25 | — | 27.6% | ||
| Q3 25 | — | 29.6% | ||
| Q2 25 | — | 22.2% | ||
| Q1 25 | — | 23.4% | ||
| Q4 24 | — | 16.3% | ||
| Q3 24 | — | 10.5% | ||
| Q2 24 | — | 14.4% | ||
| Q1 24 | — | 20.7% |
现金转化率MDXGRKLB
| Q4 25 | 1.64× | — | ||
| Q3 25 | 1.75× | — | ||
| Q2 25 | 1.50× | — | ||
| Q1 25 | 0.75× | — | ||
| Q4 24 | 2.53× | — | ||
| Q3 24 | 2.42× | — | ||
| Q2 24 | 1.24× | — | ||
| Q1 24 | 0.65× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MDXG
| Wound | $78.7M | 67% |
| Surgical | $39.4M | 33% |
RKLB
| Products | $94.0M | 52% |
| Transferred Over Time | $87.3M | 49% |
